Razor Genomics

Executive Summary

Razor Genomics is a molecular diagnostics company addressing a critical unmet need in early-stage lung cancer management. Its flagship test, RiskReveal™, analyzes a 14-gene expression signature to stratify patients with stage IA-IIA non-squamous non-small cell lung cancer (NSCLC) into low- or high-risk categories for recurrence following surgical resection. By identifying high-risk patients who are most likely to benefit from adjuvant chemotherapy, the test aims to optimize treatment decisions, reduce unnecessary toxicity in low-risk patients, and improve overall survival outcomes. The company operates in Nashville, Tennessee, and is privately held. With lung cancer remaining the leading cause of cancer death worldwide, RiskReveal addresses a growing market as more early-stage cases are detected through screening. The test has the potential to become a standard-of-care tool, pending further clinical validation and guideline inclusion. Razor Genomics faces competition from other molecular assays (e.g., molecular profiling panels) but differentiates through its focus on recurrence risk specifically for early-stage NSCLC. Key near-term catalysts include prospective study results, potential NCCN guideline updates, and commercial expansion partnerships.

Upcoming Catalysts (preview)

• Q3 2026Publication of prospective validation study for RiskReveal70% success
• Q1 2027Inclusion of RiskReveal in NCCN Clinical Practice Guidelines50% success
• Q4 2026Commercial partnership or distribution agreement for broader market access60% success